The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data
Authors:
- on behalf of the DART Virology GroupOGon behalf of the DART Virology Group
- David I. DollingDDDavid I. Dolling
- Ruth L. GoodallRGRuth L. Goodall
- James HakimJHJames Hakim
- Peter NkurunzizaPNPeter Nkurunziza
- Paula MunderiPMPaula Munderi
- David EramDEDavid Eram
- Dinah TumukundeDTDinah Tumukunde
- Moira J. SpyerMSMoira J. Spyer
- Charles F. GilksCGCharles F. Gilks
- Pontiano KaleebuPKPontiano Kaleebu
Open Access
- 21 February 2017
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 17 (1) , 1-10
Abstract
Few low-income countries have virological monitoring widely available. We estimated the virological durability of first-line antiretroviral therapy (ART) after five years of follow-up among adult Ugandan and Zimbabwean patients in the DART study, in which virological assays were conducted retrospectively. DART compared clinically driven monitoring with/without routine CD4 measurement. Annual plasma viral load was measured on 1,762 patients. Analytical weights were calculated based on the inverse probability of sampling. Time to virological failure, defined as the first viral load measurement ≥200 copies/mL after 48 weeks of ART, was analysed using Kaplan-Meier plots and Cox regression models. Overall, 65% of DART trial patients were female. Patients initiated first-line ART at a median (interquartile range; IQR) age of 37 (32–42) and with a median CD4 cell count of 86 (32–140). After 240 weeks of ART, patients initiating dual-class nucleoside reverse-transcriptase inhibitor (NRTI) -non-nucleoside reverse-transcriptase (NNRTI) regimens containing nevirapine + zidovudine + lamivudine had a lower incidence of virological failure than patients on triple-NRTI regimens containing tenofovir + zidovudine + lamivudine (21% vs 40%; hazard ratio (HR) =0.48, 95% CI:0.38–0.62; p < 0.0001). In multivariate analyses, female patients (HR = 0.79, 95% CI: 0.65–0.95; p = 0.02), older patients (HR = 0.73 per 10 years, 95% CI: 0.64–0.84; p < 0.0001) and patients with a higher pre-ART CD4 cell count (HR = 0.64 per 100 cells/mm3, 95% CI: 0.54–0.75; p < 0.0001) had a lower incidence of virological failure after adjusting for adherence to ART. No difference in failure rate between the two randomised monitoring strategies was observed (p= 0.25). The long-term durability of virological suppression on dual-class NRTI-NNRTI first-line ART without virological monitoring is remarkable and is enabled by high-quality clinical management and a consistent drug supply. To achieve higher rates of virological suppression viral-load-informed differentiated care may be required. Prospectively registered on 18/10/2000 as ISRCTN13968779 .Keywords
Funding Information
- Medical Research Council (G0600344)
- Department for International Development
- GlaxoSmithKline
- Gilead Sciences
- Boehringer Ingelheim
This publication has 26 references indexed in Scilit:
- A Single CD4 Test with 250 Cells/Mm3 Threshold Predicts Viral Suppression in HIV-Infected Adults Failing First-Line Therapy by Clinical CriteriaPLOS ONE, 2013
- Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and ZimbabweClinical Infectious Diseases, 2012
- Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final ResultsThe Journal of Infectious Diseases, 2011
- Review of inverse probability weighting for dealing with missing dataStatistical Methods in Medical Research, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48‐week randomized comparison with abacavir/zidovudine/lamivudine in HIV‐infected Ugandan adults with low CD4 cell countsHIV Medicine, 2010
- Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trialThe Lancet, 2010
- Response to combination antiretroviral therapy: variation by ageAIDS, 2008
- A Z‐theorem with Estimated Nuisance Parameters and Correction Note for ‘Weighted Likelihood for Semiparametric Models and Two‐phase Stratified Samples, with Application to Cox Regression’Scandinavian Journal of Statistics, 2008
- Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/μlAIDS, 2008